ArticleLipids in health and disease2023
Interactive effect of increased high sensitive C-reactive protein and dyslipidemia on cardiovascular diseases: a 12-year prospective cohort study.
Article in Lipids in health and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Trial
- Association of the CHG Index with the onset, progression, and prognosis of cardiovascular-kidney-metabolic syndrome: findings from two large prospective cohorts.Diabetology & metabolic syndrome · 2026Article
- Effect of Small Dense Low-Density Lipoprotein Cholesterol Combined With High-Sensitivity C-Reactive Protein on Cardiometabolic Multimorbidity: A National Cohort Study.Clinical cardiology · 2026Observational
- Associations Between Systemic Inflammatory Markers, Metabolic Dysfunction, and Liver Fibrosis Scores in Patients with MASLD.Metabolites · 2025Article
- Associations of sleep, lifestyle, and physiological markers with healthspan termination: a prospective cohort analysis.Sleep & breathing = Schlaf & Atmung · 2025Article
- Comparison of inflammatory cells, C-reactive protein, and lipid profile in atherosclerotic cardiovascular disease patients and healthy controls in Northwest Ethiopia.Scientific reports · 2025Article
- Prognostic implications of the high sensitivity C-reactive protein to albumin ratio for major cardiovascular adverse events in patients undergoing noncardiac surgery.Scientific reports · 2025Article
- Association of C-reactive protein-triglyceride glucose index with the incidence and mortality of cardiovascular disease: a retrospective cohort study.Cardiovascular diabetology · 2025Article
- High-sensitivity c-reactive protein and cardiovascular disease risk assessment in a population of type 2 diabetes mellitus patients.BMC cardiovascular disorders · 2025Article
- Elevated high-sensitivity C-reactive protein and dyslipidaemia in type 2 diabetes mellitus: implications for cardiovascular risk prediction in Nigerian patients.BMC endocrine disorders · 2025Article
- Association of obstructive sleep apnea with cardiovascular events in acute coronary syndrome patients with dual risk of remnant cholesterol and low-grade inflammation: a post-hoc analysis of the OSA-ACS study.Sleep & breathing = Schlaf & Atmung · 2025Article
- Gender-specific association between a novel atherogenic index of plasma, metabolic parameters and inflammation among obese adults.BMC endocrine disorders · 2025Article
- The predictive role of the hs-CRP/HDL-C ratio for long-term mortality in the general population: evidence from a cohort study.BMC cardiovascular disorders · 2024Article
- Exploring the Relationship between Lipid Profile, Inflammatory State and 25-OH Vitamin D Serum Levels in Hospitalized Patients.Biomedicines · 2024Article
- U-shaped relationship between non-high-density lipoprotein cholesterol and cognitive impairment in Chinese middle-aged and elderly: a cross-sectional study.BMC public health · 2024Article
- Assessment of leukocyte and systemic inflammation index ratios in dyslipidemia patients with dry eye disease: a retrospective case‒control study.Lipids in health and disease · 2024Article
- Serum high sensitive C-reactive protein level and its correlation with lipid profile among dyspeptic patients with or withoutFrontiers in cardiovascular medicine · 2024Article
- Association of the HALP Score with Dyslipidemia: A Large, Nationwide Retrospective Study.Medicina (Kaunas, Lithuania) · 2023Article
- Impact of Mental State on the Severity of Psoriasis Symptoms: A Study on Patient's Emotional Well-Being.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Correction: Interactive effect of increased high sensitive C-reactive protein and dyslipidemia on cardiovascular diseases: a 12-year prospective cohort study.Lipids in health and disease · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundDyslipidemia and inflammation are significant factors for the onset of cardiovascular diseases (CVD); however, studies regarding their interactions on the risk of CVD are scarce. This study aimed to assess the interaction of dyslipidemia and high-sensitivity C-reactive protein (hs-CRP) on CVD.
methodsThis prospective cohort enrolled 4,128 adults at baseline in 2009 and followed them up until May 2022 for collecting CVD events. Cox-proportional hazard regression analysis estimated the hazard ratios (HRs) and 95% confidence intervals (CIs) of the associations of increased hs-CRP (≥ 1 mg/L) and dyslipidemia with CVD. The additive interactions were explored using the relative excess risk of interaction (RERI) and the multiplicative interactions were assessed with HRs (95% CI) while the multiplicative interactions were assessed by the HRs (95% CI) of interaction terms.
resultsThe HRs of the association between increased hs-CRP and CVD were 1.42 (95% CI: 1.14-1.79) and 1.17 (95% CI: 0.89-1.53) among subjects with normal lipid levels and subjects with dyslipidemia, respectively. Stratified analyses by hs-CRP levels showed that among participants with normal hs-CRP (< 1 mg/L), TC ≥ 240 mg/dL, LDL-C ≥ 160 mg/dL, non-HDL-C ≥ 190 mg/dL, ApoB < 0.7 g/L, and LDL/HDL-C ≥ 2.02 were associated with CVD [HRs (95%CIs): 1.75 (1.21-2.54), 2.16 (1.37-3.41), 1.95 (1.29-2.97), 1.37 (1.01-1.67), and 1.30 (1.00-1.69), all P < 0.05, respectively]. While in the population with increased hs-CRP, only ApoAI > 2.10 g/L had a significant association with CVD [HR (95% CI): 1.69 (1.14-2.51)]. Interaction analyses showed that increased hs-CRP had multiplicative and additive interactions with LDL-C ≥ 160 mg/dL and non-HDL-C ≥ 190 mg/dL on the risk of CVD [HRs (95%CIs): 0.309 (0.153-0.621), and 0.505 (0.295-0.866); RERIs (95%CIs): -1.704 (-3.430-0.021 and - 0.694 (-1.476-0.089), respectively, all P < 0.05].
conclusionOverall our findings indicate negative interactions between abnormal blood lipid levels and hs-CRP on the risk of CVD. Further large-scale cohort studies with trajectories measurement of lipids and hs-CRP might verify our results as well explore the biological mechanism behind that interaction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.